Vannappagari V - Search Results

1

Incident type 2 diabetes mellitus after initiation of common HIV antiretroviral drugs.

Hsu R, Brunet L, Fusco JS, Mounzer K, Vannappagari V, Henegar CE, Van Wyk J, Curtis L, Lo J, Fusco GP. Hsu R, et al. Among authors: vannappagari v. AIDS. 2021 Jan 1;35(1):81-90. doi: 10.1097/QAD.0000000000002718. AIDS. 2021. PMID: 33048874

2

Prevalence, severity, and duration of thrombocytopenia among HIV patients in the era of highly active antiretroviral therapy.

Vannappagari V, Nkhoma ET, Atashili J, Laurent SS, Zhao H. Vannappagari V, et al. Platelets. 2011;22(8):611-8. doi: 10.3109/09537104.2011.582526. Epub 2011 May 25. Platelets. 2011. PMID: 21612330 Free article.

3

Association between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry.

Vannappagari V, Koram N, Albano J, Tilson H, Gee C. Vannappagari V, et al. BJOG. 2016 May;123(6):910-6. doi: 10.1111/1471-0528.13542. Epub 2015 Aug 12. BJOG. 2016. PMID: 26269220 Free PMC article.

4

Psychiatric Symptoms in Patients Receiving Dolutegravir.

Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, Hsu R, Fusco J, Quercia R, Aboud M, Curtis L. Fettiplace A, et al. Among authors: vannappagari v. J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):423-431. doi: 10.1097/QAI.0000000000001269. J Acquir Immune Defic Syndr. 2017. PMID: 27984559 Free PMC article.

5

Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.

Stainsby CM, Perger TM, Vannappagari V, Mounzer KC, Hsu RK, Henegar CE, Oyee J, Urbaityte R, Lane CE, Carter LM, Pakes GE, Shaefer MS. Stainsby CM, et al. Among authors: vannappagari v. Pharmacotherapy. 2019 Jan;39(1):40-54. doi: 10.1002/phar.2196. Epub 2018 Dec 11. Pharmacotherapy. 2019. PMID: 30414209 Free PMC article.

6

Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database.

Hsu R, Fusco J, Henegar C, Mounzer K, Wohlfeiler M, Vannappagari V, Aboud M, Curtis L, Fusco G. Hsu R, et al. Among authors: vannappagari v. Ther Adv Drug Saf. 2018 Oct 29;9(12):675-686. doi: 10.1177/2042098618798350. eCollection 2018 Dec. Ther Adv Drug Saf. 2018. PMID: 30546862 Free PMC article.

7

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA^® observational database: a cohort study.

Mounzer K, Hsu R, Fusco JS, Brunet L, Henegar CE, Vannappagari V, Stainsby CM, Shaefer MS, Ragone L, Fusco GP. Mounzer K, et al. Among authors: vannappagari v. AIDS Res Ther. 2019 Jan 16;16(1):1. doi: 10.1186/s12981-019-0217-3. AIDS Res Ther. 2019. PMID: 30651100 Free PMC article.

8

Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings.

Nance RM, Vannappagari V, Smith K, Johannes CB, Calingaert B, Saltus CW, Mayer KH, Whitney BM, Rodriguez B, Moore RD, Eron JJ, Geng E, Mathews WC, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC, Crane HM. Nance RM, et al. Among authors: vannappagari v. J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):572-577. doi: 10.1097/QAI.0000000000002075. J Acquir Immune Defic Syndr. 2019. PMID: 31107299 Free PMC article.

9

Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe.

Neesgaard B, Pelchen-Matthews A, Ryom L, Florence E, Peters L, Roen A, Svedhem V, Clarke A, Benfield T, Mitsura V, Moreno S, Beniowski M, Begovac J, Matulionyte R, Trofimova T, Elbirt D, Kundro M, Vullo V, Behrens G, Staub T, Ragone L, Vannappagari V, Lundgren J, Mocroft A; EuroSIDA study. Neesgaard B, et al. Among authors: vannappagari v. AIDS. 2019 Nov 1;33(13):2013-2024. doi: 10.1097/QAD.0000000000002320. AIDS. 2019. PMID: 31335807

10

Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review.

Vannappagari V, Ragone L, Henegar C, van Wyk J, Brown D, Demarest J, Quercia R, St Clair M, Underwood M, Gatell JM, de Ruiter A, Aboud M. Vannappagari V, et al. Antivir Ther. 2019;24(6):393-404. doi: 10.3851/IMP3331. Antivir Ther. 2019. PMID: 31503008

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters